Anti-amyloid immunotherapies in Alzheimer's disease: Are future prescribers prepared? Insights of a French national survey - PubMed
5 hours ago
- #Alzheimer's disease
- #medical survey
- #immunotherapy
- Anti-amyloid immunotherapies are newly authorized for Alzheimer's disease in the European Union.
- A 2024 French national survey assessed practitioners' knowledge on indications and risk management, finding most knew general indications, but 19.1% would consider prescribing without AD biomarkers.
- Side effects were correctly identified, though specific knowledge on amyloid-related imaging abnormalities was lacking.
- Practitioners from tertiary memory clinics showed better knowledge on indications and side effects compared to others.